Colleen Moretti

The triplet therapy should become the new standard of care for this patient population, according to recent data.

Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.

According to the phase 3 ATLAS trial, radiotherapy can be administered with next-generation hormonal therapy in phase 3 trials of patients with high-risk localized or locally advanced prostate cancer.

In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.

Ibrutinib combined with bendamustine and rituximab extended the highest progression-free survival rate ever reported for this patient population, in the phase 3 SHINE study.

According to a survey, some Black patients with metastatic breast cancer harbor distrust toward clinical trials, which has impacted the number of Black patients who participate.

New data presented during the Genitourinary Cancers Symposium support the using cabozantinib after immunotherapy without new safety signals.

While no significant difference in overall survival benefit between the treatment groups was observed, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

New results from the CAPTIVATE study demonstrated that treatment with ibrutinib and venetoclax in the first-line setting of patients with CLL continues to elicit durable responses to placebo.

In patients with metastatic castration resistant prostate cancer, sabizabulin was well tolerated and associated with significant and durable objective tumor responses

Future studies on genitourinary cancer may be limited as many currently lack data on how smoking impacts outcomes in this patient population.

Phase 2 research highlights a wellness modality that may improve outcomes in men with prostate cancer.

Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.

Consistent efficacy was seen with selpercatinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Treatment with aumolertinib led to improved progression free survival and duration of response in patients with advanced non-small cell lung caner with epidermal growth factor receptor, compared with gefitinib.

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.

Nivolumab plus cabozantinibreportedly improved health-related quality of life for patients with advanced renal cell carcinoma when compared to treatment with sunitinib.